Estimated mean sojourn time associated with hemoccult sensa for detection of proximal and distal colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 10, 2012, Pages 1722-1730

  Zheng, Wenying ^a   Rutter, Carolyn M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER DIAGNOSIS; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DESCENDING COLON; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN SOJOURN TIME; META ANALYSIS; OCCULT BLOOD; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; STATISTICAL MODEL; TIME; TUMOR LOCALIZATION;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84867324920     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0561     Document Type: Article

References (51)

1. Whitlock EP, Lin J, Liles E, Beil T, Fu R, O'Connor E, et al. Screening for colorectal cancer: an updated systematic review. Portland: Oregon Evidence-based Practice Center; 2008. Report No:08-05-05124-EF-1.
2. Aschele C, Bergamo F, Lonardi S. Chemotherapy for operable and advanced colorectal cancer. Cancer Treat Rev 2009 35:509-16.
3. Graham JS, Cassidy J. Adjuvant therapy in colon cancer. Expert Rev Anticancer Ther 2012;12:99-109.
4. Gyrd-Hansen D, Sogaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol 1997;26:1172-81. (Pubitemid 28010434)
5. Launoy G, Smith TC, Duffy SW, Bouvier V. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer 1997;73:220-4. (Pubitemid 27448822)
6. Prevost TC, Launoy G, Duffy SW, Chen HH. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches. Am J Epidemiol 1998;148:609-19. (Pubitemid 128471709)
7. Pinsky PF. Estimation and prediction for cancer screening models using deconvolution and smoothing. Biometrics 2001;57:389-95. (Pubitemid 32488594)
8. Jouve JL, Remontet L, Dancourt V, Lejeune C, Benhamiche AM, Faivre J, et al. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br J Cancer 2001;84:1477-81. (Pubitemid 32579339)
9. Wu D, Erwin D, Rosner GL. Estimating key parameters in FOBT screening for colorectal cancer. Cancer Causes Control 2009;20:41-6.
10. Beckman Coulter Inc; 2012 [cited 2012 Aug 30]. Available from: www. beckmancoulter.com/wsrportal/wsr/diagnostics/clinical-products/ rapid-diagnostics/hemoccult-sensa/index.htm
11. Web of Science; 2012 [cited 2012 Aug 30]. Available from: wokinfo.com/products-tools/multidisciplinary/webofscience/
12. Academic Search Complete; 2012 [cited 2012 Aug 30]. Available from: www.ebscohost.com/academic/academic-search-complete
13. Chappell FM, Raab GM, Wardlaw JM. When are summary ROC curves appropriate for diagnostic meta-analyses? Stat Med 2009;28:2653-68.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
15. Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009;9:80.
16. Shih YC, Zhao L, Elting LS. Does medicare coverage of colonoscopy reduce racial/ethnic disparities in cancer screening among the elderly? Health Aff (Millwood) 2006;25:1153-62. (Pubitemid 44188251)
17. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003;124:544-60. (Pubitemid 36169269)
18. Zauber AG, Winawer SJ, O'Brien M J, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687-96.
19. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK, (eds). SEER cancer statistics review, 1973 -1996. National Cancer Institute. Bethesda, MD, 1999.
20. Duffy SW, Chen HH, Tabar L, Day NE. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Stat Med 1995;14:1531-43.
21. Day NE, Walter SD. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics 1984;40:1-14.
22. Paci E, Duffy SW. Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986). Int J Epidemiol 1991;20:852-8.
23. Thomas A, Spiegelhalter DJ, Gilks WR. BUGS: a program to perform Bayesian inference using Gibbs sampling. In:Bernando JM, Berger JO, Dawid AP, editors. Bayesian statistics 4: proceedings of the fourth Valencia International Meeting. England: Clarendon Press; 1992. p. 837-42.
24. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci 1992;7:457-511.
25. Berger JO. Statistical decision theory and Bayesian analysis. 2nd ed. New York: Springer-Verlag; 1985.
26. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9. (Pubitemid 26017953)
27. Rozen P, Knaani J, Samuel Z. Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia. Dig Dis Sci 1997;42:2064-71. (Pubitemid 27501991)
28. Rennert G, Rennert HS, Miron E, Peterburg Y. Population colorectal cancer screening with fecal occult blood test. Cancer Epidemiol Biomarkers Prev 2001;10:1165-8. (Pubitemid 33064304)
29. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462-70.
30. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149:441-50.
31. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-37.
32. Protiva P. Colorectal cancer screening pathways. In: Anderson JC, Kahi CJ, editors. Colorectal cancer screening, clinical gastroenterology. New York: Springer Science + Business Media LLC; 2011. p. 1-5.
33. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev 2010;31:31-8.
34. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18. (Pubitemid 46224239)
35. Jass JR. Molecular heterogeneity of colorectal cancer: implications for cancer control. Surg Oncol 2007;16(Suppl 1):S7-9.
36. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70. (Pubitemid 26358996)
37. Jass JR. Hyperplastic polyps of the colorectum-innocent or guilty? Dis Colon Rectum 2001;44:163-6.
38. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst 2001;93:1307-13. (Pubitemid 32910571)
39. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004;53:1137-44. (Pubitemid 38961968)
40. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008;68:8541-6.
41. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008;3:e3698.
42. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87, e3.
43. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9. (Pubitemid 23167612)
44. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al.CpGisland methylator phenotype, microsatellite instability,BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
45. Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011;11:344.
46. St John DJ, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA. Comparison of the specificity and sensitivity of Hemoccult and Hemo- Quant in screening for colorectal neoplasia. Ann Intern Med 1992;117:376-82.
47. Harmston C, Hunter J, Wong L. Does the location of screen-detected cancers differ from that seen in the unscreened population? Colorectal Dis 2010;12:324-6.
48. Schenck AP, Peacock SC, Klabunde CN, Lapin P, Coan JF, Brown ML. Trends in colorectal cancer test use in the medicare population, 1998-2005. Am J Prev Med 2009;37:1-7.
49. Holden DJ, Jonas DE, Porterfield DS, Reuland D, Harris R. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann Intern Med 2010;152:668-76.
50. Richardson IC, Rim SH, Plescia M. Vital signs: colorectal cancer screening among adults aged 50-75 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2010;59:808-12.
51. Huang CS, Farraye FA, Yang S, O'Brien MJ. The clinical significance of serrated polyps. Am J Gastroenterol 2011;106:229-40.